NMI 139

Drug Profile

NMI 139

Alternative Names: NO-albumin

Latest Information Update: 16 Mar 2008

Price : $50

At a glance

  • Originator NitroMed
  • Developer Boston Scientific Corporation; NitroMed
  • Class Albumins; Nitroso compounds
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis

Most Recent Events

  • 28 Sep 1999 Preclinical development for Coronary artery restenosis in USA (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top